Summary
Xin Zhang is a Senior Scientist in San Diego with 11 years of hands-on experience across small molecule drug discovery, antibody engineering, and RNA vaccine platforms. At Turning Point Therapeutics they lead biology efforts for early-stage discovery projects, building cell-based assays, inducible knockdown models, and acquired resistance models that directly supported IND-enabling programs. Prior roles include developing protein expression and antibody production platforms at Pfizer and advancing VEE-based self-replicating RNA vaccines at MIT, giving them rare cross-disciplinary fluency from synthetic biology to in vivo pharmacology. They are skilled in high-throughput screening, SAR-informed assay development, and translational pharmacology for oncology targets such as ROS1. Known for turning mechanistic hypotheses into deployable cellular models, Xin also mentors junior scientists and interns to accelerate project timelines. Their pragmatic “Demo or Die” ethos reflects a bias toward tangible experimental validation and rapid iteration.
11 years of coding experience
Master’s Degree, Biology, Master’s Degree, Biology at Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences